Real world risk of infusion reactions and effectiveness of front-line obinutuzumab plus chlorambucil compared with other frontline treatments for chronic lymphocytic leukemia

Peer Review reports

Original Submission
15 Jun 2021	Submitted	Original manuscript
3 Oct 2021	Reviewed	Reviewer Report - Monia Marchetti
12 Oct 2021	Reviewed	Reviewer Report
15 Nov 2021	Author responded	Author comments - Versha Banerji
20 Nov 2021	Reviewed	Reviewer Report - Monia Marchetti
26 Jan 2022	Reviewed	Reviewer Report
Resubmission - Version 2
15 Nov 2021	Submitted	Manuscript version 2
Publishing
31 Jan 2022	Editorially accepted
6 Feb 2022	Article published	10.1186/s12885-022-09256-2

Back to article page